James Terwilliger

Newport Coast Securities

Image: James  Terwilliger

James Terwilliger joined The Benchmark Company in January 2012 to cover small- to mid-cap medical device and healthcare services companies. He has more than 10 years of equity research experience covering companies in the cardiology, oncology, orthopedics, technology and service sectors. Previous to working with Benchmark, Terwilliger was the executive managing director of healthcare research at Duncan Williams Inc. His other Wall Street affiliations include Morgan Keegan & Company, Sander Morris Harris Inc. and Needham & Company. Terwilliger's healthcare industry experience includes sales and marketing with Johnson & Johnson Healthcare Systems Inc. and as a healthcare consultant for Ernst & Young. He was also president of Neurorecovery Inc., a biopharmaceutical company focused on neurological conditions. In 2005, Terwilliger was recognized by The Wall Street Journal as an All-Star Analyst for stock price performance for medical devices and equipment. He was also recognized in 2002 by StarMine as one of the top medical device analysts for earnings accuracy. Terwilliger holds a master's degree in public health from Yale School of Medicine with a focus on healthcare management and healthcare finance.

Recent Quotes

"EXAC posted strong Q4/12 results and it remains an attractive acquisition candidate."

— James Terwilliger, The Benchmark Company LLC (2/28/13)
more >

"We are encouraged by the strong revenue momentum EXAC posted in Q4/12."

— James Terwilliger, Benchmark (1/29/13)
more >

"EXAC posted strong Q3/12 results, as revenue of $51.3M exceeded our $49.5M estimate."

— James Terwilliger, Benchmark Capital (11/2/12)
more >

"EXAC has one of the fastest growth profiles in the industry."

The Life Sciences Report Interview with James Terwilliger (9/6/12)
more >

"We believe EXAC continue to drive top-line revenue growth."

— James Terwilliger, Benchmark (8/14/12)
more >

Due to permission requirements, not all quotes are shown.